Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HCmed Innovations CoTPE:6934 +1.50%18 EV-to-EBIT is -18.97 as of Aug. 25, 2026. GuruFocus rates TPE:6934 with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 476 Medical Devices & Instruments companies, HCmed Innovations Co ranks worse than 210083.82% on this metric.
HCmed Innovations Co (TPE:6934) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
HCmed Innovations Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$2,029.0 Mil.
HCmed Innovations Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-122.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCmed Innovations Co EV-to-EBIT Related Terms
HCmed Innovations Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for HCmed Innovations Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, HCmed Innovations Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCmed Innovations Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HCmed Innovations Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where HCmed Innovations Co's EV-to-EBIT falls into.
HCmed Innovations Co's current Enterprise Value is NT$2,321.7 Mil.
HCmed Innovations Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-122.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCmed Innovations Co (TPE:6934) has a EV-to-EBIT of -18.97 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on HCmed Innovations Co and its competitors. According to the industry distribution chart, HCmed Innovations Co ranks #999999 out of 476 companies in the Medical Devices & Instruments industry.
Is HCmed Innovations Co's EV-to-EBIT too high?
HCmed Innovations Co's current EV-to-EBIT is -18.97. Based on the distribution chart, HCmed Innovations Co ranks #999999 out of 476 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, HCmed Innovations Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does HCmed Innovations Co's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HCmed Innovations Co ranks #999999 out of 476 companies for EV-to-EBIT. This places HCmed Innovations Co in the lower half of its industry. The industry median EV-to-EBIT is 19.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.00, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on HCmed Innovations Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCmed Innovations Co's current EV-to-EBIT is -18.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCmed Innovations Co stock overvalued right now?
HCmed Innovations Co (TPE:6934) has a current EV-to-EBIT of -18.97. The current EV-to-EBIT is -18.97. HCmed Innovations Co's overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For HCmed Innovations Co (TPE:6934), the current EV-to-EBIT is -18.97 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HCmed Innovations Co Ltd is engaged in designing, developing, manufacturing and selling drug delivery system. It is focused on inhalation therapy to create integrated drug nebulizer combination products featuring nebulization therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs. Its product includes Pulmogine. Geographically, the company operates in America, Europe, Asian and African regions.
18GF Score
Get the complete analysis for TPE:6934
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6934 has been successfully added to your 
